COVID-19 Testing for the Essential Workforce
Learn about our efforts to test people on the front line and how you can help.
MiraKind has a pipeline of open and pending studies to identify new biomarkers of disease risk, as well as to help determine the best ways to protect the health of individuals with biomarkers of interest, such as the KRAS-variant.
Dating back to 2002, there have been several studies stating that hormone replacement therapy (HRT) increases the risk for breast cancer. HRT was vilified, and many women stopped using or never started using HRT. However, those findings do not apply to all women. For women with the KRAS-variant, HRT may be of a particular benefit.
This is a study to determine if women with the KRAS-variant are more likely to develop pregnancy associated breast cancer, which is breast cancer diagnosed within five years of being pregnant.
This study will investigate the 'triggers' for an initial cancer diagnosis in KRAS-variant positive individuals.
This study will investigate 'triggers' for a second cancer diagnosis in KRAS-variant individuals.